Immunology pioneer argenx (NASDAQ:ARGX) delivered its first-ever year of operating profitability in 2025, powered by a massive commercial expansion of its flagship FcRn blocker, VYVGART.
The company reported full-year product net sales of $4.2 billion, a nearly 90% increase over the previous year, resulting in approximately $1.1 billion in operating income.
The financial milestone underscores the rapid global adoption of VYVGART across its approved indications, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
By year-end, the company was reaching approximately 19,000 patients globally, nearly doubling its reach from 2024.
Beyond the balance sheet, argenx cleared significant clinical and regulatory hurdles.
The company announced positive topline results from the Phase 3 ADAPT OCULUS trial in ocular myasthenia gravis (oMG), which met its primary endpoint with statistically significant improvements in patient-reported outcomes.
Furthermore, the FDA has set a PDUFA target action date of May 10, 2026, for the company’s supplemental Biologics License Application (sBLA) for seronegative gMG—a subset of patients currently lacking targeted therapeutic options.
Management reiterated its "Vision 2030" strategy, which aims to treat 50,000 patients and secure 10 labeled indications by the end of the decade.
The company’s pipeline remains a primary focus, with several registrational readouts expected through 2026 and 2027, including data for primary immune thrombocytopenia (ITP) and myositis.
As argenx matures from a R&D-heavy biotech into a profitable commercial powerhouse, it continues to invest in the next wave of its immunology franchise.
This includes advancing early-stage candidates like ARGX-119 and expanding its FcRn portfolio to maintain its leadership in the increasingly competitive autoimmune market.